When it comes to medical cannabis in Germany, there has historically been a fairly stark contrast in medical cannabis patient density in different regions of the country. Regional medical cannabis patient density in Germany was the focus of a recent market analysis conducted by Frankfurt-based Bloomwell Group.

“In relation to the population, the number of medical cannabis patients is significantly higher in southern Germany than in the north. The share is particularly below the national average in eastern German states. However, the number of patients in eastern German states has risen disproportionately since the removal of medical cannabis from the Narcotics Act (BtMG) on April 1, 2024. This trend toward nationwide normalization has continued over the last twelve months.” Bloomwell wrote in a press release obtained by the International Cannabis Business Conference.

Below is a statistical breakdown by region of the share of self-paying medical cannabis patients in relation to the national average after April 1st, 2024, according to the analysis:

• Saarland = +29.6 percent
• Bavaria = +27.6 percent
• Rhineland-Palatinate = +17.9 percent
• Hesse = +16.5 percent
• Baden-Württemberg = +14.4 percent
• Brandenburg = -31.3 percent
• Mecklenburg-Western Pomerania = -18.2 percent
• Saxony = -28.3 percent
• Saxony-Anhalt = -22.5 percent
• Thuringia = -18.9 percent

“Nevertheless, the share of medical cannabis patients in eastern German states has already significantly caught up since the removal of medical cannabis from the Narcotics Act (BtMG) on April 1, 2024. Since then, the growth factor—which describes the development of medical cannabis patients converted per 100,000 inhabitants—is 314 in Saxony-Anhalt, 184 in Mecklenburg-Western Pomerania, and 118 in Brandenburg. By comparison, it is 25 in Saarland and 17 in Bavaria over the same period.” Bloomwell stated.

“This normalization has intensified in the last year: For example, the share in Saxony-Anhalt approached the national average to within -9.7 percent from July 2025 to June 2026. Before the removal from the BtMG, this value was -83.8 percent. In Bavaria, the value from July 2025 to June 2026 was still 12.1 percent above the average. Before April 1, 2024, it was 150.5 percent.” the company added.

“Our new overview map of nationwide care with medical cannabis sends a positive signal: Digitalization has enabled access for cannabis patients even in regions where there is a lack of comprehensive, established doctors with experience in the field of medical cannabis. Furthermore, information about legal digital therapy access is reaching those affected more and more effectively. Illegal self-medication, which carries risks, is therefore increasingly falling behind nationwide. Medical cannabis is now playing a leading role in combating the illegal market throughout Germany.” Dr. med. Julian Wichmann, Co-Founder and Managing Director of Bloomwell GmbH, said.

The average price for medical cannabis flower continues to decrease in Germany as the market matures. Medical cannabis flower price compression is a trend that has been occurring in Germany and other larger legal medical cannabis markets in recent years. According to the analysis by Bloomwell, the average price for medical cannabis flowers per gram dropped to four euros in the second quarter of 2026.

“The fact that the reimbursement of medical cannabis flowers by health insurance funds is being cut in an ‘austerity law’ is completely absurd in view of the price development in the out-of-pocket sector. The real problem has long been the outdated price regulation, which has completely decoupled itself from market dynamics. Until the law comes into force, health insurance funds are reimbursing up to 19 euros per gram of medical cannabis flowers. We have approached health insurance funds several times in the past to find more efficient ways of providing care for patients together. Instead, the legislator is now leaving chronically ill people, some of whom have been well-adjusted to their medication for years, completely out in the cold. Our offer for dialogue and cooperation remains valid.” Niklas Kouparanis, Co-Founder and CEO of the Bloomwell Group GmbH, said.